Fosun's Seventh CIIE Attendance: Guo Guangchang's Vision of China's High-Level Openness
Thursday, Nov 7, 2024 12:17 am ET
2min read Fosun International, a prominent Chinese conglomerate, marked its seventh consecutive attendance at the China International Import Expo (CIIE) in Shanghai, highlighting its commitment to global innovation and China's high-level openness. Guo Guangchang, Chairman of Fosun International, expressed confidence in China's openness as a significant historical opportunity for growth and collaboration.
Fosun's participation in CIIE has been instrumental in driving its growth and innovation. The company has successfully transformed several "exhibits" into tangible products, significantly benefiting healthcare in China. Key highlights include the Ion Robotic Bronchoscopy, designed for lung cancer diagnosis, and the V2 model of Exablate Neuro, a non-invasive treatment for neurological conditions. These advancements, supported by the CIIE's "spillover effect," have entered the market to serve Chinese patients, transforming from "exhibits" into "products."
Fosun's open innovation ecosystem has significantly contributed to its success at CIIE and beyond. By leveraging independent R&D, collaborative development, licensing, and industry investment, Fosun has continually transformed 'exhibits' into 'products' and converted overseas partners into 'investors.' This approach has enabled Fosun to introduce global innovations and export local developments, enhancing patient access to advanced therapies.
Fosun's commitment to addressing unmet clinical needs in neurological disease treatments has significantly enhanced its reputation and growth at CIIE and in the broader market. By introducing the V2 model of the "Exablate Neuro FUS system" at CIIE, Fosun showcased its dedication to innovation and improving patient lives. This non-invasive treatment option for essential tremor and Parkinson's disease has received CE certification in Europe and FDA approval in the United States, demonstrating its global potential. With over 20,000 patients treated worldwide, the technology's success has further solidified Fosun's position as a leader in neurological disease treatment transformation.
Fosun's strategic approach to leveraging CIIE as a platform for international collaboration and innovation has significantly contributed to its long-term success and growth in the healthcare sector. As a seven-time attendee, Fosun has transformed the expo into a vital conduit for China's high-level openness and global integration, enabling it to transition various "exhibits" into tangible products and convert overseas partners from "exhibitors" into "investors." This approach has facilitated the introduction of global innovations and the export of local developments, enhancing patient access to advanced therapies.
Guo Guangchang, Chairman of Fosun International, firmly believes that China remains a significant opportunity for global development. Together with more overseas companies and global partners, Fosun will promote more cutting-edge innovations to take root in China, moving forward and achieving mutual success on the grand stage of the CIIE.
In conclusion, Fosun's seventh attendance at CIIE underscores its commitment to global innovation and China's high-level openness. Through its open innovation ecosystem and dedication to addressing unmet clinical needs, Fosun has successfully driven growth and enhanced its reputation in the healthcare sector. As China continues to open up, Fosun's strategy will likely accelerate the localization of advanced medical devices and promote more cutting-edge innovations, further integrating China into the global healthcare industry.
Fosun's participation in CIIE has been instrumental in driving its growth and innovation. The company has successfully transformed several "exhibits" into tangible products, significantly benefiting healthcare in China. Key highlights include the Ion Robotic Bronchoscopy, designed for lung cancer diagnosis, and the V2 model of Exablate Neuro, a non-invasive treatment for neurological conditions. These advancements, supported by the CIIE's "spillover effect," have entered the market to serve Chinese patients, transforming from "exhibits" into "products."
Fosun's open innovation ecosystem has significantly contributed to its success at CIIE and beyond. By leveraging independent R&D, collaborative development, licensing, and industry investment, Fosun has continually transformed 'exhibits' into 'products' and converted overseas partners into 'investors.' This approach has enabled Fosun to introduce global innovations and export local developments, enhancing patient access to advanced therapies.
Fosun's commitment to addressing unmet clinical needs in neurological disease treatments has significantly enhanced its reputation and growth at CIIE and in the broader market. By introducing the V2 model of the "Exablate Neuro FUS system" at CIIE, Fosun showcased its dedication to innovation and improving patient lives. This non-invasive treatment option for essential tremor and Parkinson's disease has received CE certification in Europe and FDA approval in the United States, demonstrating its global potential. With over 20,000 patients treated worldwide, the technology's success has further solidified Fosun's position as a leader in neurological disease treatment transformation.
Fosun's strategic approach to leveraging CIIE as a platform for international collaboration and innovation has significantly contributed to its long-term success and growth in the healthcare sector. As a seven-time attendee, Fosun has transformed the expo into a vital conduit for China's high-level openness and global integration, enabling it to transition various "exhibits" into tangible products and convert overseas partners from "exhibitors" into "investors." This approach has facilitated the introduction of global innovations and the export of local developments, enhancing patient access to advanced therapies.
Guo Guangchang, Chairman of Fosun International, firmly believes that China remains a significant opportunity for global development. Together with more overseas companies and global partners, Fosun will promote more cutting-edge innovations to take root in China, moving forward and achieving mutual success on the grand stage of the CIIE.
In conclusion, Fosun's seventh attendance at CIIE underscores its commitment to global innovation and China's high-level openness. Through its open innovation ecosystem and dedication to addressing unmet clinical needs, Fosun has successfully driven growth and enhanced its reputation in the healthcare sector. As China continues to open up, Fosun's strategy will likely accelerate the localization of advanced medical devices and promote more cutting-edge innovations, further integrating China into the global healthcare industry.